This study underscores the potential of combining PTT with a therapeutic cancer vaccine adjuvanted with TLR5 ligand and an ICI (TLIF-PTT+FlaB Vax + αPD-1) as a potent therapeutic strategy for DD-Her2/neu tumors. Here, ERBB2 is linked to cancer.